Thursday 21 November 2024
Time
Presentation title
09:00 - 10:00
Arrival and registration
10:00 - 10:15
Welcome / Opening ceremony
Location: A1
Presentation category:
Therapeutic apheresis, haematological indications, Therapeutic apheresis, non-haematological indications
Presentation summary
This educational session will review the indications of red cell exchange transfusions.
10:15 - 11:00
Helmut Borberg Lecture and Award
Location: A1
Hans Vrielink - Transfusion and Apheresis Medicine Specialist - Sanquin Blood Supply Foundation visit profile
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest, Haemapheresis in children, Technical aspects of haemapheresis, including venous access and replacement fluids, Therapeutic apheresis, haematological indications, Therapeutic apheresis, non-haematological indications
Presentation summary
A brief overview of the work history in apheresis in the past and future as award winner.
Abstract details
A brief overview of the work history in apheresis in the past and future as award winner of the professor doctor Helmut Borberg Lecture and Award.
11:00 - 11:10
Very short break to give the opportunity to select the preferred session.
11:10 - 11:40
11:10 - 11:40
CAR-T in solid tumors
Location: A1
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
11:40 - 12:10
Coffee / tea break
11:40 - 12:10
11:40 - 12:40
The optimization of cell collections
Location: A1
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
12:10 - 12:40
Informed consent for cell donors
Location: Gauguin
Claudia Ootjers - Hematologist and Transfusion Medicine Specialist - Leiden University Medical Centre visit profile
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
Presentation summary
In this presentation it will be summarized what the key elements are in an informed consent for cell donors. Attention will be paid to: clarity, purpose, voluntariness, confidentiality, withdrawal, questions and comprehension. It will be explained why these components help to protect the rights and welfare of cell donors while promoting ethical standards in medical and research practices.
12:40 - 13:00
Red Blood Cell Exchange indications (SCD, Malaria, Pertussis)
Location: A1
Presentation category:
Therapeutic apheresis, haematological indications, Therapeutic apheresis, non-haematological indications
Presentation summary
This educational session will review the indications of red cell exchange transfusions.
13:00 - 14:00
14:00 - 14:30
Presentation summary
Presented by Linda Christiaans
14:00 - 14:30
14:30 - 15:00
Red Blood Cell Exchange: one versus two arm system
Location: Gauguin
Presentation category:
Technical aspects of haemapheresis, including venous access and replacement fluids
14:30 - 15:00
Educational platform tailored to personnel involved in ATMP development
Location: A1
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
Presentation summary
The development of advanced therapeutic medicinal products (ATMP) requires the close collaboration between many different professionals. These professionals also need additional training regarding these novel products. Unfortunately, these trainings a scattered and many people struggle with finding the right training opportunities. We have established a platform with an overview of available trainings with a short course description, target population and costs.
Abstract details
We will discuss the difficulties in aligning professionals in the development of ATMPs. We will discuss the website developed by DARE-NL that gives an overview of courses and how to navigate it and we will discuss the opportunity to register available courses on this platform.
15:00 - 15:30
CAR-T: allogenic T-cel
Location: Gauguin
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
Presentation summary
The rapid development of CAR-T cell therapy has also revealed important challenges that limit the feasibility of cost-effective, easier and broader application.The use of allogeneic healthy donor-derived T cells has been suggested as an alternative, readily available source of CAR-T cells. However, their use requires substantial genome engineering.The technology of induced pluripotent stem cells (iPSC) offers new perspectives for the production of immunotherapeutic cellular products with multi-plex modifications.
15:00 - 15:30
CD34 gene therapy in Metachromatic Leukodystrophy and Hurlers Disease
Location: A1
Caroline Lindemans - Pediatric Bone marrow transplant specialist - Prinses Maxima Centrum ; UMC Utrecht visit profile
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest, Haemapheresis in children, Therapeutic apheresis, non-haematological indications
15:30 - 16:00
Coffee / tea break
16:00 - 16:30
Use of CD+ cells in cellular therapies
Location: A1
Andreas Buser - Prof. Dr. - Regional Blood Transfusion Service, Swiss Red Cross, Basel and haematology, University Hospital Basel, Switzerland visit profile
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
Presentation summary
This presentation focuses on the procurement and use of CD34+ stem cells for cellular therapies wirth emphasis on stem cell transplantation.
16:30 - 17:00
Extracorporeal photoapheresis
Location: A1
Presentation category:
Cellular therapy, including CAR-T’s and stem cell mobilization/harvest
17:00 - 17:30
Effect of Daratumumab on the collection of CD34+ cells
Location: A1
Marjolein Appelman visit profile
17:30 - 18:00
Gather in the lobby of the Marriott hotel Madurodam
18:00 - 22:30
Social program at Madurodam